Acarbose can prevent Type 2 diabetes and cardiovascular disease in subjects with impaired glucose tolerance: The STOP-NIDDM trial

被引：0

作者：

Chiasson, J ^{[1
]}

Josse, RG ^{[1
]}

Gomis, R ^{[1
]}

Hanefeld, M ^{[1
]}

Karasik, A ^{[1
]}

Laakso, M ^{[1
]}

机构：

[1] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada

来源：

DIABETOLOGIA | 2002年 / 45卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

312

引用

页码：A104 / A104

页数：1

共 50 条

[1] Acarbose reduces incidence of type 2 diabetes and of myocardial infarction in subjects with impaired glucose tolerance: The STOP-NIDDM trial
Hanefeld, M
Temelkova-Kurktschiev, TTK
[J]. EUROPEAN HEART JOURNAL, 2002, 23 : 609 - 609
[2] Efficacy of acarbose to prevent type 2 diabetes is different in subgroups of subjects with impaired glucose tolerance: The STOP - NIDDM trial
Hanefeld, M
Josse, RG
Gomis, R
Karasik, A
Laakso, M
Chiasson, JL
[J]. DIABETOLOGIA, 2002, 45 : A104 - A105
[3] Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data
J.-L. Chiasson
R. G. Josse
R. Gomis
M. Hanefeld
A. Karasik
M. Laakso
[J]. Diabetologia, 2004, 47 : 969 - 975
[4] Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data
Chiasson, JL
Josse, RG
Gomis, R
Hanefeld, M
Karasik, A
Laakso, M
[J]. DIABETOLOGIA, 2004, 47 (06) : 969 - 975
[5] Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data - Response
Sawicki, PT
Kaiser, T
[J]. DIABETOLOGIA, 2004, 47 (06) : 976 - 977
[6] Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial
Chiasson, JL
Josse, RG
Gomis, R
Hanefeld, M
Karasik, A
Laakso, M
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (04): : 486 - 494
[7] Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data
P. T. Sawicki
T. Kaiser
[J]. Diabetologia, 2004, 47 : 976 - 977
[8] Acarbose prevents cardiovascular events in patients with impaired glucose tolerance/early diabetes. Results of the STOP-NIDDM ECG evaluation
Schwarzmaier-D'Assie, A
Zeymer, U
Petzinna, D
Slany, J
Chiasson, JL
[J]. CIRCULATION, 2003, 108 (17) : 749 - 750
[9] Acarbose prevents cardiovascular events in patients with impaired glucose tolerance. Results of the STOP-NIDDM electrocardiogram evaluation
Zeymer, U
Schwarzmaier-D'Assie, A
Petzinna, D
Chiasson, JL
[J]. EUROPEAN HEART JOURNAL, 2003, 24 : 133 - 133
[10] Importance of white blood cell count and alanine aminotransferase as predictors of type 2 diabetes in subjects with impaired glucose tolerance: the STOP-NIDDM trial
Koehler, C
Hanefeld, M
Westermeier, T
Chiasson, JL
[J]. DIABETOLOGIA, 2005, 48 : A251 - A252

← 1 2 3 4 5 →